Federal contract award
75N94019F00125
HIV AND OTHER IMPAACT RELATED INFECTIOUS DISEASE STUDIES
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NICHD |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | HHSN275201800001I |
| Set-aside | Not reported |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $5.7M |
| Current contract value | $5.7M |
| Potential contract value / ceiling | $5.7M |
| Start date | Apr 1, 2019 |
| Current end date | Feb 28, 2026 |
| Potential end date | Feb 28, 2026 |
| Latest award activity | Sep 23, 2024 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 9 of 9 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 23, 2024 | P00008 | $60.0K | HIV AND OTHER IMPAACT RELATED INFECTIOUS DISEASE STUDIES |
| Sep 11, 2024 | P00007 | $-5.7M | HIV AND OTHER IMPAACT RELATED INFECTIOUS DISEASE STUDIES |
| Jul 8, 2024 | P00006 | $187.5K | HIV AND OTHER IMPAACT RELATED INFECTIOUS DISEASE STUDIES |
| Dec 21, 2023 | P00005 | $0 | HIV AND OTHER IMPAACT RELATED INFECTIOUS DISEASE STUDIES |
| Apr 19, 2022 | P00004 | $-611.8K | HIV AND OTHER IMPAACT RELATED INFECTIOUS DISEASE STUDIES |
| Mar 24, 2022 | P00003 | $-983.6K | HIV AND OTHER IMPAACT RELATED INFECTIOUS DISEASE STUDIES |
| May 21, 2020 | P00002 | $0 | HIV AND OTHER IMPAACT RELATED INFECTIOUS DISEASE STUDIES |
| Sep 9, 2019 | P00001 | $-2.0M | HIV AND OTHER IMPAACT RELATED INFECTIOUS DISEASE STUDIES |
| Apr 1, 2019 | 0 | $14.8M | HIV AND OTHER IMPAACT RELATED INFECTIOUS DISEASE STUDIES |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.